BIOMAT Database Logo BIOMAT Database Logo

Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. 1990

B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Department of Medical Oncology, University Hospital, Groningen, The Netherlands.

30 patients with chemotherapy-related leukopenia (white cells 1.0 x 10(9)/l or lower) and fever (temperature 38.5 degrees C or higher) were treated in a double-blind randomised trial with standard antibiotics and 7 days of intravenously administered recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, 2.8 micrograms/kg per day) or placebo. GM-CSF administration resulted in a faster percentage increase of peripheral neutrophil count after 2 and 3 days of treatment, except in patients treated with ablative chemotherapy and autologous bone-marrow transplantation. However, GM-CSF did not shorten the period of fever or antibiotic administration. No side-effects were observed; in particular tumour necrosis factor alpha and interleukin-6 did not increase in the 5 GM-CSF patients tested. These data suggest that a subgroup of patients with chemotherapy-related leukopenia and fever may benefit from GM-CSF treatment in view of the observed effects on neutrophil count.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias

Related Publications

B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
[Clinical study of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced leukopenia].
September 1994, Zhonghua zhong liu za zhi [Chinese journal of oncology],
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Recombinant human granulocyte-macrophage colony-stimulating factor produces fever.
April 1988, Lancet (London, England),
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor for chemotherapy-induced leukopenia in patients with non-small-cell lung cancer.
January 1994, Cancer chemotherapy and pharmacology,
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte-macrophage colony-stimulating factor in neutropenic children with malignancies.
January 1995, Pediatric hematology and oncology,
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Clinical experience with recombinant human granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor.
April 1989, Seminars in hematology,
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Recombinant human granulocyte-macrophage colony-stimulating factor in children with chemotherapy-induced neutropenia.
January 1992, Medical and pediatric oncology,
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Efficacy of recombinant human granulocyte-macrophage colony-stimulating factor in rhesus monkeys.
January 1987, Annals of the New York Academy of Sciences,
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on HIV-related leukopenia: a randomized, controlled clinical study.
October 1997, AIDS (London, England),
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Recombinant human granulocyte-macrophage colony-stimulating factor in AIDS.
March 1988, The New England journal of medicine,
B Biesma, and E G de Vries, and P H Willemse, and W J Sluiter, and P E Postmus, and P C Limburg, and A C Stern, and E Vellenga
Clinical studies with recombinant human granulocyte-macrophage colony-stimulating factor.
January 1990, International journal of cell cloning,
Copied contents to your clipboard!